An Open Label, Prospective, Observational, Non-interventional Study of Bevacizumab in Combination With Interferon Alpha-2a for the First-line Treatment of Patients With Advanced and/or Metastatic Renal Cell Carcinoma.

Trial Profile

An Open Label, Prospective, Observational, Non-interventional Study of Bevacizumab in Combination With Interferon Alpha-2a for the First-line Treatment of Patients With Advanced and/or Metastatic Renal Cell Carcinoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Interferon alpha-2a (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 16 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Sep 2011 Planned end date changed from 1 Dec 2014 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 14 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top